专利检索 ap:("INOTREM" OR "APHP (ASSISTANCE PUBLIQUE—HÔPITAUX DE PARIS)" OR "INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)" OR "UNIVERSITÉ DE LORRAINE") AND inv:"Amir Boufenzer" 第 1 页

1.

发明授权
Methods and kits for predicting the risk of having a cardiovascular disease or event 有权

公开(公告)号：US10948498B2

公开(公告)日：2021-03-16

申请号：US14910715

申请日：2014-08-08

申请人： INOTREM , APHP (ASSISTANCE PUBLIQUE—HÔPITAUX DE PARIS) , INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITÉ DE LORRAINE

发明人： Marc Derive , Sebastien Gibot , Hafid Ait-Oufella , Amir Boufenzer , Tabasomme Simon , Nicolas Danchin

IPC分类号： G01N31/00 , G01N33/53 , G01N33/68 , G01N33/566

摘要： A cardiovascular event or disease is prevented or treated in a subject by measuring the expression level of soluble Triggering Receptors Expressed on Myeloid cells-1 (sTREM-1) level in a sample from the subject and comparing it to a reference level. Based on this comparison, subjects that are at risk of having or developing a cardiovascular event or disease are identified, and administered a suitable therapy.

2.

发明申请
INHIBITING PEPTIDES DERIVED FROM TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS-1 (TREM-1) TREM-LIKE TRANSCRIPT 1 (TLT-1) AND USES THEREOF 有权
标题翻译：抑制在MYELOID细胞-1（TREM-1）TREM-LIKE转录物1（TLT-1）上表达的触发受体衍生的肽及其用途

公开(公告)号：US20150232531A1

公开(公告)日：2015-08-20

申请号：US14426562

申请日：2013-09-09

申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) , UNIVERSITÉ DE LORRAINE

发明人： Sebastien Gibot , Amir Boufenzer , Hafid Ait-Oufella , Marc Derive

IPC分类号： C07K14/705

CPC分类号： C07K14/70503

摘要： The present invention relates to a peptide comprising at least 6 consecutive amino acid selected from the amino acid sequence SEQ ID NO: 2 and a function-conservative variant. The invention also relates to a peptide comprising at least 6 consecutive amino acid selected from the amino acid sequence SEQ ID NO: 1 or SEQ ID NO: 2 and a function-conservative variant for use in the treatment of a cardiovascular disease.

摘要翻译： 本发明涉及包含至少6个选自氨基酸序列SEQ ID NO：2的连续氨基酸和功能保守变体的肽。本发明还涉及包含至少6个选自氨基酸序列SEQ ID NO：1或SEQ ID NO：2的连续氨基酸的肽和用于治疗心血管疾病的功能保守变体。

3.

发明授权
Mesenchymal stem cells obtained from Wharton's jelly for the treatment of sepsis 有权

公开(公告)号：US11963984B2

公开(公告)日：2024-04-23

申请号：US16488253

申请日：2018-02-28

申请人： UNIVERSITÉ DE LORRAINE , CENTRE HOSPITALIER RÉGIONAL UNIVERSITAIRE DE NANCY

发明人： Danièle Bensoussan , Sébastien Gibot , Loïc Reppel , Caroline Laroye , Amir Boufenzer , Léonore Avercenc , Céline Huselstein

IPC分类号： A61K35/51

CPC分类号： A61K35/51

摘要： The disclosure relates to human mesenchymal stem cells from Wharton's jelly, a method for preparing them, and the therapeutic uses thereof, in particular for the treatment of sepsis and specifically septic shock. The treatment may involve the administration to a subject in need thereof a pharmaceutical composition including the human mesenchymal stem cells from Wharton's jelly and a pharmaceutically acceptable excipient.